LUMO News and Press, Lumos Pharma Inc.

AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...

AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...

2024-05-15 15:10:28 ET Lumos Pharma, Inc. (LUMO) Q1 2024 Earnings Conference Call May 15, 2024, 08:30 AM ET Company Participants Lisa Miller - Vice President, Investor Relations Rick Hawkins - Chief Executive Officer & Chairman John McKew - President & Ch...

2024-05-15 01:15:48 ET More on Lumos Pharma Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lumos Pharma Financial information for Lumos Pharma Read the full article on Seeking Alpha For further details see: Lumos ...

Outcome from End-of-Phase 2 Meeting Supportive of a Placebo-Controlled Phase 3 Trial Updated 12 and 24-Month Data from Phase 2 OraGrowtH210 and OraGrowtH212 Trials Continue to Show Oral LUM-201 Achieves Significant Increase in Growth from Baseline, Durable Effect to 24 Months ...

2024-05-14 15:20:37 ET More on Lumos Pharma Lumos Pharma, Inc. (LUMO) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Lumos Pharma Historical earnings data for Lumos Pharma Financial information for Lumos Pharma Read the full...

2024-05-14 10:01:42 ET Major earnings expected before the bell on Wednesday include: Cresco Labs ( OTCQX:CRLBF ) Dynatrace ( DT ) Hut 8 ( HUT ) monday.com ( MNDY ) 22nd Century Group ( XXII ) Read the full article on Seeking Alpha For ...

AUSTIN, Texas, May 09, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report first quarter 2024 financial results before market open on Wednesday, May 15, 2024. The company will hos...

Apartment Investment and Management Company (AIV) is expected to report for Q1 2024 Shopify Inc. Class A Subordinate (SHOP) is expected to report $0.08 for Q1 2024 Beyond Meat Inc. (BYND) is expected to report $-0.68 for Q1 2024 Instructure Holdings Inc. (INST) is expected to report $...

Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...